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Introduction: In a previous screening of the whole CFTR gene in order to establish
the spectrum of mutations in a representative sample of Portuguese patients with
CBAVD, we identiﬁed 3 novel disease-causing mutations in both nucleotide binding
domains (NBDs). P439S lies within NBD1, P1290S and E1401K in NBD2. The
present study analysed the effects of the 3 mutations on CFTR processing and
intracellular transport. In addition, cAMP-regulated Cl− conductances produced by
the 3 mutants were assessed.
Methods: Mutations generated in an expression plasmid were transiently over-
expressed in HEK 293 cells. Biosynthetic pathways were analyzed by Western
blotting and confocal microscopy. Measurement of the cAMP-regulated Cl− con-
ductance was assessed by iodide inﬂux assay and whole-cell patch-clamp.
Results: Mutant CFTR exhibited a maturation pattern similar to the wild-type
CFTR, but the total amount of mature P439S-CFTR and P1290S-CFTR was
reduced. E1401K-CFTR was localized in cell membrane, whereas P439S-CFTR
and P1290S-CFTR were mainly detected in cytoplasm. All mutants showed reduced
cAMP-activated Cl− conductances.
Conclusions: Decreased Cl− conductances detected for P439S-CFTR and P1290S-
CFTR are explained by reduced amounts of mature protein in cell membrane,
whereas for E1401K-CFTR a defective channel was conﬁrmed. The reduced Cl−
conductance of all mutants is sufﬁcient to affect the normal development of a
susceptible tissue such as the vas deferens, although not to cause cystic ﬁbrosis.
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Idiopathic seminal ﬂuid hyperviscosity (ISHV), a major cause of impaired fertility
in human males, has a prevalence of approximately 4%. Its pathogenesis is usually
unknown, but some previous results (Rossi et al., Fertil. Steril. 2004;82:1316−22)
have suggested that an altered CFTR genotype be involved, at least in some cases.
The variability of the CFTR gene was investigated in 40 ISHV patients and in
125 random subjects by performing an extensive sequencing of the coding and of
the ﬂanking intronic regions of this gene, searching for: (a) pathogenic mutations;
(b) Splicing-Error Prone (SEP) haplotypes, namely the (TG)12T5 and (TG)12T7
repeats in intron 8, known to cause a substantial increase in the frequency of
incorrectly spliced RNA transcripts; (c) genomic variants with a still undeﬁned
functional role. We have sofar sequenced, in all our samples, 11 CFTR exons
(i.e. 1855 coding bp out of 4443) and about 880 non-coding bp of the adjacent
intronic regions. The ISHV group, as compared to controls, was found to have
a signiﬁcantly higher frequency of subjects with at least one CFTR pathogenic
mutation or a SEP haplotype (0.525±0.079 vs 0.176±0.034) or with at least one
CFTR variant (0.825±0.060 vs 0.456±0.045).
Although the functional relevance of genomic variants is still to be assessed,
the higher frequency, in the ISHV target population, of classic mutations, SEP
haplotypes and/or variants in the CFTR gene supports the hypothesis that this
overall genomic speciﬁcity be signiﬁcantly associated to the ISHV phenotype.
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The lung disease of cystic ﬁbrosis (CF) is characterized by a self-sustaining cycle
of airway obstruction, infection, and inﬂammation. Such processes are in part
regulated by transcription factors. Among them, NRF2 (NF-E2-related factor)
plays a pivotal role in protection against oxidative stress-induced pulmonary
inﬂammation and IRFs (Interferon regulatory factors) are involved in bacterial
infection response. Our laboratory evidenced that both ubiquitous (such as SRF
and YY1) and tissue-speciﬁc (such as FoxA2) transcription factors are implicated
in the transcriptional regulation of the CFTR gene. Recently and interestingly, in
the CFTR minimal promoter we identiﬁed new cis-regulatory elements including an
overlapping binding site for NRF2 and IRFs. By using EMSAs, we demonstrated
the following DNA/protein bindings: DNA/NRF2 and DNA/IRFs. A functional
analysis, by co-transfections assays, showed while NRF2 and IRF1 are repressors,
IRF2 is an activator. Although additional studies are required to further elucidate
the regulatory mechanisms contributing to the CFTR expression control, we present
the ﬁrst evidence that transcription factors implicated in inﬂammation and infection
processes, regulate the CFTR gene transcriptional activity. Better understanding of
the role of these factors could identify new therapeutic targets for a more exquisite
regulation of both inﬂammatory and infectious pathways that ultimately contribute
to lung damage in CF. It will be interesting to test whether ceramids, already
involved in different therapeutic aspects of the CF disease (host-defense against
P. aeruginosa, inhibition of IL-8 disease and reduction of airway anion secretion),
could be more beneﬁcial therapeutic agents, for instance through NRF2 cytoplasmic
relocalization.
Supported by: VLM.
28* Study of the unfolded protein response (UPR) in cystic ﬁbrosis
(CF)
M. Kerbiriou, P. Trouve´, C. Fe´rec. INSERM, Brest, France
Cystic ﬁbrosis transmembrane conductance regulator (CFTR) functions as a chlo-
ride (Cl−) channel in the apical membrane of epithelial cells. The most common
mutation in CF is a deletion of a phenylalanine residue at position 508 (DF508).
The DF508-CFTR protein is incorrectly folded and accumulates in the endoplasmic
reticulum (ER). This accumulation could trigger the UPR pathway which leads to
a global decrease of the protein synthesis in cells and to apoptosis. Our aim was
to determine whether UPR is triggered in DF508-CFTR expressing cells. Because
infection and inﬂammation observed in CF can trigger UPR we studied the cell
susceptibility to exogenous UPR inducers tunicamycin (Tu) and thapsigargin (Tg).
UPR was studied by the expression of two speciﬁc markers: the glucose-regulated
protein 78 (GRP78) and the transcription factor 6 (ATF6) which were compared
in wild type (Wt) and in DF508-CFTR transfected cells. The model was validated
by immunoﬂuorescence and by Cl− channel function studies (SPQ) and we showed
by western blotting that both GRP78 and ATF6 are over-expressed in DF508-
CFTR cells. Furthermore ATF6 was activated in DF508-CFTR cells since it was
cleaved and relocated to the nuclei. The SPQ results indicated that the inhibition
of GRP78 expression by a speciﬁc siRNA had no signiﬁcant effect upon the CFTR
activity whereas the inhibition of ATF6 expression induced an increased Cl− channel
function of CFTR and DF508-CFTR. The response of Wt and DF508-CFTR cells
to Tu and Tg were not different. In conclusion we show that UPR is triggered in
DF508-CFTR cells and that a decreased ATF6 expression leads to an increased
CFTR and DF508-CFTR function. We propose that the decreased ATF6 expression
is a therapeutic target.
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